格隆汇1月28日丨塞力医疗(603716.SH)在投资者互动平台表示，目前公司暂无尼帕病毒病原学检测试剂/ 仪器或治疗药物储备，也暂无相关产品代理。我们的布局重点在"高危急性感染的早期识别与预警"能 力：基于战略投资并引进的Inflammatix TriVerity急性感染与脓毒症检测，可在症状极早期通过mRNA转 录组信号实现感染类型判断（病毒/细菌/非感染）及重症/脓毒症风险分层。对尼帕这类疑似病例， TriVerity可作为急诊/发热门诊的早期预警与分诊升级工具，提示更高等级隔离与监护、支持更快启动确 诊检测与救治流程，最终确诊仍需病原学检测配合。 （原标题：塞力医疗(603716.SH)：暂无尼帕病毒病原学检测试剂/仪器或治疗药物储备） ...

Core Viewpoint - The company currently does not have any Nipah virus-related testing reagents, instruments, or treatment drugs in its inventory, nor does it have any products for agency sales. The focus is on early identification and warning capabilities for high-risk acute infections through the Inflammatix TriVerity™ system, which can assist in early triage and monitoring for suspected cases of Nipah virus [1]. Group 1 - The company received an inquiry regarding its preparedness for the Nipah virus outbreak in West Bengal, India, which has affected several healthcare workers [1]. - The company confirmed that it does not possess any Nipah virus-related testing reagents or treatment options at this time [1]. - The company's strategic focus is on early identification and warning for high-risk acute infections, utilizing the Inflammatix TriVerity™ system for early infection type determination and risk stratification [1]. Group 2 - The Inflammatix TriVerity™ system can provide early warning and triage support in emergency settings for suspected cases, facilitating quicker diagnosis and treatment processes [1]. - The company emphasizes that while TriVerity™ can assist in early detection, final confirmation still requires pathogen detection methods [1].

格隆汇1月28日丨塞力医疗(603716.SH)在投资者互动平台表示，目前公司暂无尼帕病毒病原学检测试剂/ 仪器或治疗药物储备，也暂无相关产品代理。我们的布局重点在"高危急性感染的早期识别与预警"能 力：基于战略投资并引进的Inflammatix TriVerity急性感染与脓毒症检测，可在症状极早期通过mRNA转 录组信号实现感染类型判断（病毒/细菌/非感染）及重症/脓毒症风险分层。对尼帕这类疑似病例， TriVerity可作为急诊/发热门诊的早期预警与分诊升级工具，提示更高等级隔离与监护、支持更快启动确 诊检测与救治流程，最终确诊仍需病原学检测配合。 ...

Group 1 - The core viewpoint of the article highlights a collective rise in A-share pharmaceutical commercial stocks, driven by government initiatives to enhance pharmaceutical services and retail drug sales [1] - The Ministry of Commerce and nine other departments issued a document proposing measures to improve pharmaceutical services, enhance pharmacy service capabilities, and promote prescription circulation to improve the purchasing experience [1] - The document encourages pharmaceutical retail companies to engage in horizontal mergers and acquisitions, and to innovate in drug sales channels, including the sale of innovative drugs and reference preparations through retail pharmacies [1] Group 2 - Notable stock performances include: - Renmin Tongtai (人民同泰) with a rise of 10.04% and a total market value of 72.43 billion [2] - Yifeng Pharmacy (益丰药房) increasing by 10.02% with a market cap of 301 billion [2] - Luyuan Pharmaceutical (鹭燕医药) up by 7.76% with a market value of 70.13 billion [2] - Dacelin (大参林) rising by 6.63% with a market cap of 242 billion [2] - Jiuzhoutong (九州通) increasing by 5.27% with a market value of 282 billion [2] - Other companies showing significant gains include Zhongyao Holdings (重药控股) up by 4.89%, Yaoyigou (药易购) up by 4.42%, and Haiwang Biological (海王生物) up by 4.41% [2]

Group 1 - The core point of the article is that Sely Medical reported a total of 105,076 shareholders as of January 10, 2026 [2]

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.19% on January 15, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - Notable gainers included: - RunDa Medical (603108) with a closing price of 20.04, up 1.83% and a trading volume of 700,800 shares [1] - LiuYao Group (603368) closed at 18.58, up 0.60% with a trading volume of 79,700 shares [1] - LaoBaiXing (603883) closed at 16.11, up 0.50% with a trading volume of 226,200 shares [1] - Significant decliners included: - Huaren Health (301408) closed at 23.81, down 19.99% with a trading volume of 491,100 shares [2] - ShangYu PingMin (301017) closed at 18.50, down 13.75% with a trading volume of 373,900 shares [2] - YaoYiGou (300937) closed at 37.40, down 11.79% with a trading volume of 121,400 shares [2] Capital Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 990 million yuan from institutional investors, while retail investors had a net inflow of 977 million yuan [2] - The table of capital flow indicates that: - LaoBaiXing (603883) had a net inflow of 46.10 million yuan from institutional investors [3] - JiuZhouTong (600998) had a net inflow of 40.43 million yuan from institutional investors [3] - RunDa Medical (603108) had a net inflow of 37.80 million yuan from institutional investors [3]

Core Viewpoint - The company, Sely Medical, announced the convening of its first extraordinary shareholders' meeting on January 7, 2026, to discuss the proposal for expanding its business scope and corresponding amendments [2] Group 1 - The company has recently completed the industrial and commercial change of its business scope and the filing procedures for its Articles of Association [2] - The company has obtained a new business license issued by the Administrative Approval Bureau of the Dongxihu District in Wuhan [2]

Core Insights - The 20th National Congress of the Communist Party of China has identified biomanufacturing as one of the six key future industries for the 14th Five-Year Plan, marking it as a significant direction for national strategic planning [1] - The implementation of the "Regulations on the Management of Clinical Research and Clinical Translation Applications of Biomedical New Technologies" in May 2026 will provide robust policy support for the industry [1] - Under the dual policy benefits, China's pharmaceutical industry is transitioning from "follow-up innovation" to "systematic innovation," with a focus on source innovation and the integration of AI and biotechnology [1] Industry Opportunities - Seer Medical is transitioning from a traditional medical supply chain service provider to a "technology-driven biomanufacturing platform," capitalizing on three key opportunities presented by the 14th Five-Year Plan: focus on cutting-edge fields like gene and cell therapy, the necessity of full-chain manufacturing capabilities, and the deep integration of AI and biotechnology [2][3] Technological Developments - Seer Medical is focusing on "AI intelligent diagnosis" and "innovative therapies," developing a diversified layout system, including an automatic intelligent microbial drug sensitivity testing instrument and an intelligent expert diagnostic system in collaboration with Fudan University [3] - The company is also advancing the TriVerity™ AI-assisted triage system for acute infections and sepsis, aiming to provide cutting-edge molecular diagnostic solutions [4] Innovations in Drug Development - The company’s subsidiary, Huajiyuan, is progressing with a new class I therapeutic hypertension vaccine, which has received clinical trial approval and is expected to revolutionize chronic disease management [5] - The "Haishi Lingxi" digital system for mental health has been implemented in clinical settings, focusing on brain disease digital treatment [6] Global Strategy - Seer Medical positions itself as a "dual-circulation value hub," leveraging global technology and local manufacturing to enhance resource and value circulation [7] - The company is actively introducing advanced biomanufacturing technologies and solutions to emerging markets, demonstrating the efficiency of "Chinese manufacturing" [8] Future Directions - The company aims to build an AI-enabled ecosystem in biomanufacturing, focusing on smart hospital management and therapeutic vaccines, aligning with the national development plan [9] - Seer Medical is committed to becoming a key player in the cell therapy industrialization infrastructure, emphasizing the integration of core equipment, compliant production, and clinical channels [10]

Core Viewpoint - The company has announced a temporary shareholders' meeting on January 7, 2026, to review the expansion of its business scope and amendments to its Articles of Association [1] Group 1: Business Scope Changes - The company has completed the business scope change and the filing procedures for the amended Articles of Association, obtaining a new business license [1] - The expanded business scope now includes the leasing of Class I medical devices, general equipment repair, and the leasing of Class III medical devices, as well as pharmaceutical wholesale [1] Group 2: Regulatory Compliance - The company has disclosed the full text of the amended Articles of Association on the Shanghai Stock Exchange website, confirming the completion of the registration process [1]

塞力斯医疗科技集团股份有限公司 章 程 2026 年 1 月 1 | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 5 | | 第一节 | 股份发行 5 | | 第二节 | 股份增减和回购 6 | | 第三节 | 股份转让 7 | | 第四章 | 股东和股东会 8 | | 第一节 | 股东的一般规定 8 | | 第二节 | 控股股东和实际控制人 10 | | 第三节 | 股东会的一般规定 11 | | 第四节 | 股东会的召集 15 | | 第五节 | 股东会的提案与通知 16 | | 第六节 | 股东会的召开 17 | | 第七节 | 股东会的表决和决议 20 | | 第五章 | 董事和董事会 23 | | 第一节 | 董事的一般规定 23 | | 第二节 | 董事会 26 | | 第三节 | 独立董事 31 | | 第四节 | 董事会专门委员会 33 | | 第六章 | 高级管理人员 35 | | 第七章 | 财务会计制度、利润分配和审计 37 | | 第一节 | 财务会计制度 37 | | 第二节 | 内部审计 40 | | 第三节 ...